Corrigendum to “Systematic combination screening reveals synergism between rapamycin and sutent against human lung cancer” (Cancer Letter (2014) 342 (159–166) (S0304383513006435) (10.1016/j.canlet.2019.12.001));Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer

Cancer Letters

Volumn 342, Issue 1, 2014, Pages 159-166

  Li, Xian ^a   Tong, Lin Jiang ^a   Ding, Jian ^a   Meng, Ling Hua ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Combination; Non small cell lung cancer; Rapamycin; Sunitinib

Indexed keywords

AT 7519; BORTEZOMIB; CISPLATIN; DACTINOMYCIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; MITOMYCIN; NAVELBINE; PALBOCICLIB; PEMETREXED; PROTEIN KINASE B; RAPAMYCIN; SORAFENIB; SUNITINIB; TOPOTECAN; UNCLASSIFIED DRUG; VASCULOTROPIN; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; ENDOTHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RAT;

MAMMALIA;

EID: 84887613247     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2019.12.001     Document Type: Erratum

References (30)

1. Buck E., Eyzaguirre A., Brown E., Petti F., McCormack S., Haley J.D., Iwata K.K., Gibson N.W., Griffin G. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Molecular Cancer Therapeutics 2006, 5:2676-2684.
2. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
3. Chen S.M., Liu J.L., Wang X., Liang C., Ding J., Meng L.H. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR. Biochemical Pharmacology 2012, 83:1183-1194.
4. Choo A.Y., Yoon S.O., Kim S.G., Roux P.P., Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:17414-17419.
5. Chou T.-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Research 2010, 70:440-446.
6. Dancey J.E., Chen H.X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nature Reviews. Drug Discovery 2006, 5:649-659.
7. L. Ding, G. Getz, D.A. Wheeler, E.R. Mardis, M.D. McLellan, K. Cibulskis, C. Sougnez, H. Greulich, D.M. Muzny, M.B. Morgan, L. Fulton, R.S. Fulton, Q. Zhang, M.C. Wendl, M.S. Lawrence, D.E. Larson, K. Chen, D.J. Dooling, A. Sabo, A.C. Hawes, H. Shen, S.N. Jhangiani, L.R. Lewis, O. Hall, Y. Zhu, T. Mathew, Y. Ren, J. Yao, S.E. Scherer, K. Clerc, G.A. Metcalf, B. Ng, A. Milosavljevic, M.L. Gonzalez-Garay, J.R. Osborne, R. Meyer, X. Shi, Y. Tang, D.C. Koboldt, L. Lin, R. Abbott, T.L. Miner, C. Pohl, G. Fewell, C. Haipek, H. Schmidt, B.H. Dunford-Shore, A. Kraja, S.D. Crosby, C.S. Sawyer, T. Vickery, S. Sander, J. Robinson, W. Winckler, J. Baldwin, L.R. Chirieac, A. Dutt, T. Fennell, M. Hanna, B.E. Johnson, R.C. Onofrio, R.K. Thomas, G. Tonon, B.A. Weir, X. Zhao, L. Ziaugra, M.C. Zody, T. Giordano, M.B. Orringer, J.A. Roth, M.R. Spitz, Wistuba, II, B. Ozenberger, P.J. Good, A.C. Chang, D.G. Beer, M.A. Watson, M. Ladanyi, S. Broderick, A. Yoshizawa, W.D. Travis, W. Pao, M.A. Province, G.M. Weinstock, H.E. Varmus, S.B. Gabriel, E.S. Lander, R.A. Gibbs, M. Meyerson, R.K. Wilson, Somatic mutations affect key pathways in lung adenocarcinoma, Nature 455 (2008) 1069-1075.
8. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Reviews. Cancer 2009, 9:550-562.
9. Faivre S., Demetri G., Sargent W., Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nature Reviews Drug Discovery 2007, 6:734-745.
10. Ghayad S.E., Cohen P.A. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Patents on Anti-Cancer Drug Discovery 2010, 5:29-57.
11. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
12. Holmes K., Roberts O.L., Thomas A.M., Cross M.J. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cellular Signalling 2007, 19:2003-2012.
13. Homicsko K., Lukashev A., Iggo R.D. RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. Cancer Research 2005, 65:6882-6890.
14. Houghton P.J., Morton C.L., Gorlick R., Lock R.B., Carol H., Reynolds C.P., Kang M.H., Maris J.M., Keir S.T., Kolb E.A., Wu J., Wozniak A.W., Billups C.A., Rubinstein L., Smith M.A. Stage 2 combination testing of rapamycin with cytotoxic agents by the pediatric preclinical testing program. Molecular Cancer Therapeutics 2010, 9:101-112.
15. Houghton P.J., Morton C.L., Kolb E.A., Gorlick R., Lock R., Carol H., Reynolds C.P., Maris J.M., Keir S.T., Billups C.A. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatric Blood & Cancer 2008, 50:799-805.
16. Huang J., Manning B.D. A complex interplay between Akt, TSC2, and the two mTOR complexes. Biochemical Society Transactions 2009, 37:217.
17. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., Kovacevic Z., Lesovoy V., Schmidt-Wolf I.G., Barbarash O., Gokmen E., O'Toole T., Lustgarten S., Moore L., Motzer R.J., Global A.T. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. The New England Journal of Medicine 2007, 356:2271-2281.
18. Huynh H., Chow P.K., Palanisamy N., Salto-Tellez M., Goh B.C., Lee C.K., Somani A., Lee H.S., Kalpana R., Yu K., Tan P.H., Wu J., Soong R., Lee M.H., Hor H., Soo K.C., Toh H.C., Tan P. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. Journal of Hepatology 2008, 49:52-60.
19. Huynh H., Teo C.C., Soo K.C. Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Molecular Cancer Therapeutics 2007, 6:2959-2966.
20. Kodera Y., Katanasaka Y., Kitamura Y., Tsuda H., Nishio K., Tamura T., Koizumi F. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Research 2011, 13:R66.
21. Kummar S., Chen H.X., Wright J., Holbeck S., Millin M.D., Tomaszewski J., Zweibel J., Collins J., Doroshow J.H. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nature Reviews. Drug Discovery 2010, 9:843-856.
22. Laplante M., Sabatini D.M. MTOR signaling in growth control and disease. Cell 2012, 149:274-293.
23. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., Grunwald V., Thompson J.A., Figlin R.A., Hollaender N., Urbanowitz G., Berg W.J., Kay A., Lebwohl D., Ravaud A., Group R.-S. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
24. Novello S., Scagliotti G.V., Rosell R., Socinski M.A., Brahmer J., Atkins J., Pallares C., Burgess R., Tye L., Selaru P., Wang E., Chao R., Govindan R. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. British Journal of Cancer 2009, 101:1543-1548.
25. O'Reilly K.E., Rojo F., She Q.-B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Research 2006, 66:1500-1508.
26. Soria J.C., Shepherd F.A., Douillard J.Y., Wolf J., Giaccone G., Crino L., Cappuzzo F., Sharma S., Gross S.H., Dimitrijevic S., Di Scala L., Gardner H., Nogova L., Papadimitrakopoulou V. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2009, 20:1674-1681.
27. Stephan S., Datta K., Wang E., Li J., Brekken R.A., Parangi S., Thorpe P.E., Mukhopadhyay D. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2004, 10:6993-7000.
28. Waqar S.N., Gopalan P.K., Williams K., Devarakonda S., Govindan R. A phase I trial of sunitinib and rapamycin in patients with advanced non-small cell lung cancer. Chemotherapy 2013, 59:8-13.
29. Xu C.X., Li Y., Yue P., Owonikoko T.K., Ramalingam S.S., Khuri F.R., Sun S.Y. The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo. PloS One 2011, 6:e20899.
30. Yap T.A., Garrett M.D., Walton M.I., Raynaud F., de Bono J.S., Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Current Opinion in Pharmacology 2008, 8:393-412.